Literature DB >> 28499860

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.

Ibiayi Dagogo-Jack1, David Fabrizio2, Jochen Lennerz3, Alexa B Schrock2, Lauren Young2, Mari Mino-Kenudson3, Subba R Digumarthy4, Rebecca S Heist1, Siraj M Ali2, Vincent A Miller2, Alice T Shaw5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28499860      PMCID： PMC5610630          DOI： 10.1016/j.jtho.2017.04.023

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  8 in total

Review 1.  Cancer of unknown primary site.

Authors:  Gauri R Varadhachary; Martin N Raber
Journal:  N Engl J Med       Date:  2014-08-21       Impact factor: 91.245

2.  Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.

Authors:  Eunice L Kwak; Leanne G Ahronian; Giulia Siravegna; Benedetta Mussolin; Darrell R Borger; Jason T Godfrey; Nicholas A Jessop; Jeffrey W Clark; Lawrence S Blaszkowsky; David P Ryan; Jochen K Lennerz; A John Iafrate; Alberto Bardelli; Theodore S Hong; Ryan B Corcoran
Journal:  Cancer Discov       Date:  2015-10-02       Impact factor: 39.397

Review 3.  Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors:  Alexander Drilon; Federico Cappuzzo; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-10-26       Impact factor: 15.609

4.  Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.

Authors:  Jeffrey S Ross; Kai Wang; Laurie Gay; Geoff A Otto; Emily White; Kiel Iwanik; Gary Palmer; Roman Yelensky; Doron M Lipson; Juliann Chmielecki; Rachel L Erlich; Andrew N Rankin; Siraj M Ali; Julia A Elvin; Deborah Morosini; Vincent A Miller; Philip J Stephens
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

5.  Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.

Authors:  Ultan McDermott; Raju V Pusapati; James G Christensen; Nathanael S Gray; Jeff Settleman
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

6.  Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

Authors:  Rafael Caparica; Cheng Tzu Yen; Renata Coudry; Sai-Hong Ignatius Ou; Marileila Varella-Garcia; D Ross Camidge; Gilberto de Castro
Journal:  J Thorac Oncol       Date:  2016-09-21       Impact factor: 15.609

7.  Switching benchmarks in cancer of unknown primary: from autopsy to microarray.

Authors:  George Pentheroudakis; Vassilios Golfinopoulos; Nicholas Pavlidis
Journal:  Eur J Cancer       Date:  2007-08-14       Impact factor: 9.162

8.  MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.

Authors:  Joanna H Tong; Sai F Yeung; Anthony W H Chan; Lau Y Chung; Shuk L Chau; Raymond Wai Ming Lung; Carol Y Tong; Chit Chow; Edith K Y Tin; Yau H Yu; Hui Li; Yi Pan; Wing P Chak; Calvin S H Ng; Tony S K Mok; Ka F To
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531
  8 in total
  2 in total

1.  Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.

Authors:  Elodie Belnoue; Jean-François Mayol; Susanna Carboni; Wilma Di Berardino Besson; Eloise Dupuychaffray; Annika Nelde; Stefan Stevanovic; Marie-Laure Santiago-Raber; Paul R Walker; Madiha Derouazi
Journal:  JCI Insight       Date:  2019-04-23

Review 2.  Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.

Authors:  Misty Dawn Shields; Kevin Chen; Giselle Dutcher; Ishika Patel; Bruna Pellini
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.